CC BY-NC-ND 4.0 · South Asian J Cancer 2021; 10(03): 172-174
DOI: 10.1055/s-0041-1729446
Original Article: Leukemia - Lymphoma and Myeloma

Innovator Filgrastim versus Generic Filgrastim in Hematopoietic Stem Cell Transplantation Mobilization

Sadik Husian
1  Department of Pharmacology, Pharmaceutical Sciences and Research University, New Delhi, India
,
Preethi Jeyaraman
2  Division of Hematology and Bone Marrow Transplant, Saket, New Delhi, India
,
S. K. Gupta
1  Department of Pharmacology, Pharmaceutical Sciences and Research University, New Delhi, India
,
Reeta Rai
3  Division of Transfusion Medicine, Department of Lab Medicine Transfusion Medicine, Max Super Specialty Hospital, Saket, New Delhi, India
,
Sangeeta Pathak
3  Division of Transfusion Medicine, Department of Lab Medicine Transfusion Medicine, Max Super Specialty Hospital, Saket, New Delhi, India
,
Nitin Dayal
4  Department of Lab Medicine, Max Super Specialty Hospital, Saket, New Delhi, India
,
Rahul Naithani
2  Division of Hematology and Bone Marrow Transplant, Saket, New Delhi, India
› Author Affiliations

Abstract

Methods This is a retrospective study. G-CSF was administered in the dose of 10 μg/kg subcutaneous as a single dose for 4 days. On day 5, peripheral blood stem cell (PBSC) apheresis was performed using Haemonetics MCS plus or COBE Spectra apheresis machine through a double-lumen central venous catheter. Primary outcome parameters were the total number of CD34+ HSCs/kg of recipient weight mobilized in peripheral blood and the number of days required for neutrophil and platelets engraftment, respectively.

Objective We compared the effectiveness and safety of innovator filgrastim versus generic filgrastim in patients who underwent hematopoietic stem cell transplantation (HSCT).

Results A total of 91 stem cell mobilizations was analyzed. There were 58 normal healthy donors for allogeneic HSCT and 33 patients for autologous HSCT. There was no statistically significant difference among groups in terms of total collected CD34+ cells value (p = 0.609). The mean time to neutrophil engraftment was 13.7 days in the innovator group and 13.2 days in the Grafeel group (p = 0.518). The mean time to platelet engraftment was 16.2 days in the innovator group and 14.8 days in the generic group (p = 0.435). The patient who received generic filgrastim had more febrile episodes during the course of transplantation (p = 0.020).

Conclusion Generic filgrastim was found to be comparable to original filgrastim for peripheral blood stem cell mobilization in normal healthy donors for allogeneic HSCT and patients for autologous HSCT.



Publication History

Publication Date:
04 September 2021 (online)

© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India